Investigation of the effects of herbal medicines on warfarin response in healthy subjects: A population pharmacokinetic-pharmacodynamic modeling approach

Journal of Clinical Pharmacology

Volumn 46, Issue 11, 2006, Pages 1370-1378

  Jiang, Xuemin ^a,b   Blair, Elaine Y L ^a,d   McLachlan, Andrew J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CHICAGO   (United States)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d Sanofi aventis   (Australia)

Author keywords

Anticoagulants; Asian ginseng; Ginger; Ginkgo; Herb drug interactions; Population pharmacokinetic pharmacodynamic modeling; St John's wort; Warfarin

Indexed keywords

GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; PROTHROMBIN COMPLEX; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; HERB DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; MODEL; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANTICOAGULANTS; GINGER; GINKGO BILOBA; HEALTH; HERB-DRUG INTERACTIONS; HERBAL MEDICINE; HUMANS; HYPERICUM; MALE; MEDICINE, HERBAL; MODELS, BIOLOGICAL; PANAX; PLANT EXTRACTS; WARFARIN;

EID: 33749873660     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006292124     Document Type: Article

References (41)

1. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005;45:127-132.
2. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003;3:221-230.
3. Huang SM, Lesko LJ, Williams RL. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol. 1999;39:1006-1014.
4. Ernst E. Second thoughts about safety of St John's wort. Lancet. 1999;354:2014-2016.
5. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother. 2000;34:1478-1482.
6. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ. 2004;329:27-30.
7. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2004;57:592-599.
8. Yuan CS, Wei G, Dey L, et al. American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med. 2004;141:23-27.
9. Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger. 2003;165:1868-1871.
10. Makino T, Wakushima H, Okamoto T, Okukubo Y, Deguchi Y, Kano Y. Pharmacokinetic interactions between warfarin and kangenkaryu, a Chinese traditional herbal medicine, and their synergistic action. J Ethnopharmacol. 2002;82:35-40.
11. Abdel-Rahman SM, Kauffman RE. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol. 2004;44:111-136.
12. Blesch KS, Gieschke R, Tsukamoto Y, Reigner BG, Burger HU, Steimer JL. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs. 2003;21:195-223.
13. Gobburu JV, Marroum PJ. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin Pharmacokinet. 2001;40:883-892.
14. Karlsson MO, Anehall T, Friberg LE, et al. Pharmacokinetic/ pharmacodynamic modelling in oncological drug development. Basic Clin Pharmacol Toxicol. 2005;96:206-211.
15. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol. 1998;45:229-239.
16. Chan E, McLachlan A, O'Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther. 1994;56:286-294.
17. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet. 1986;11:483-504.
18. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59:425-432.
19. Blumenthal M. Herbal Medicine: Expanded Commission E Monographs. Austin, Texas: American Botanical Council; 2000.
20. Pitsiu M, Parker EM, Aarons L, Rowland M. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults. Eur J Pharm Sci. 1993:151-157.
21. Boeckmann A, Sheiner L, Beal S. NONMEM User's Guide. San Francisco, Calif: University of California at San Francisco; 1994.
22. Holford N. WFN Bootstrap. Wings for NONMEM. 2004. Available at: http://wfn.sourceforge.net/.
23. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 1997;33:313-327.
24. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24:153-172.
25. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819-850.
26. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 2003;56:24-29.
27. Mahe I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol. 2005;59:371-374.
28. Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost. 2004;92:797-802.
29. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy. 1993;13:508-509.
30. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther. 2004;308:495-501.
31. Kitts D, Hu C. Efficacy and safety of ginseng. Public Health Nutr. 2000;3:473-485.
32. Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD. Herb-drug interactions: an evidence based approach. Curr Med Chem. 2004;11:1513-1525.
33. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61:2163-2175.
34. Williamson EM. Drug interactions between herbal and prescription medicines. Drug Saf. 2003;26:1075-1092.
35. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. 2001;7:70-86, 88-90.
36. Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. Thromb Res. 2002;108:151-160.
37. Bal Dit Sollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol. 2003;25:251-253.
38. Biber A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 2003;36:S32-S37.
39. Kressmann S, Biber A, Wonnemann M, Schug B, Blume HH, Muller WE. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol. 2002;54:1507-1514.
40. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4:39-42.
41. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004;103:2630-2635.